NANOMATERIALS COMPRISING DIAMINES

1 . A compound of Formula (A):

or its N-oxide, or a pharmaceutically acceptable salt thereof, wherein

L is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-6 hydrocarbon chain, wherein 1-2 methylene units are optionally and independently replaced with —O— or —NR b —;

L 1 is absent or an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-6 hydrocarbon chain, wherein 1-2 methylene units are optionally and independently replaced with —O— or —NR b —;

each of L 2 , L 2′ , and L 2″ is independently an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-15 hydrocarbon chain, wherein 1-5 methylene units are optionally and independently replaced with —O— or —NR b —;

each of L 3 , L 3′ , and L 3″ is independently absent or an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-10 hydrocarbon chain, wherein 1-5 methylene units are optionally and independently replaced with —O— or —NR b —;

each of X, X′, and X″ is independently absent, —OC(O)—, —C(O)O—, or —OC(O)O—;

each of R, R′ and R″ is independently hydrogen,

or an optionally substituted group selected from C 6-20 aliphatic, 3- to 12-membered saturated or partially unsaturated carbocyclyl, 7- to 12-membered saturated or partially unsaturated bridged bicyclyl having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl, wherein

at least one of R, R′, and R″ is

each L 3a is independently absent or an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-10 hydrocarbon chain, wherein 1-5 methylene units are optionally and independently replaced with —O— or —NR b —;

each R a is independently hydrogen or an optionally substituted group selected from C 6-20 aliphatic, 3- to 12-membered saturated or partially unsaturated carbocyclyl, 7- to 12-membered saturated or partially unsaturated bridged bicyclyl having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl;

R 1 is hydrogen, optionally substituted phenyl, optionally substituted 3- to 7-membered saturated or partially unsaturated carbocyclyl, optionally substituted 3- to 7-membered saturated or partially unsaturated heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, optionally substituted 8- to 10-membered bicyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, —OR 2 , —C(O)OR 2 , —C(O)SR 2 , —OC(O)R 2 ,

—OC(O)OR 2 , —CN, —N(R 2 ) 2 , —C(O)N(R 2 ) 2 , —S(O) 2 N(R 2 ) 2 , —NR 2 C(O)R 2 , —OC(O)N(R 2 ) 2 ,

—N(R 2 )C(O)OR 2 , —NR 2 S(O) 2 R 2 , —NR 2 C(O)N(R 2 ) 2 , —NR 2 C(S)N(R 2 ) 2 , —NR 2 C(NR 2 )N(R 2 ) 2 ,

—NR 2 C(CHR 2 )N(R 2 ) 2 , —N(OR 2 )C(O)R 2 , —N(OR 2 )S(O) 2 R 2 , —N(OR 2 )C(O)OR 2 ,

—N(OR 2 )C(O)N(R 2 ) 2 , —N(OR 2 )C(S)N(R 2 ) 2 , —N(OR 2 )C(NR 2 )N(R 2 ) 2 , —N(OR 2 )C(CHR 2 )N(R 2 ) 2 ,

—C(NR 2 )N(R 2 ) 2 , —C(NR 2 )R 2 , —C(O)N(R 2 )OR 2 , —C(R 2 )N(R 2 ) 2 C(O)OR 2 , —CR 2 (R 3 ) 2 ,

—OP(O)(OR 2 ) 2 , or —P(O)(OR 2 ) 2 ; or

R 1 is

or a ring selected from 3- to 7-membered saturated or partially unsaturated carbocyclyl and 3- to 7-membered saturated or partially unsaturated heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein the carbocyclyl or heterocyclyl is optionally substituted with 1-4 R 2 or R 3 groups;

each R 2 is independently hydrogen, oxo, —CN, —NO 2 , —OR 4 , —S(O) 2 R 4 , —S(O) 2 N(R 4 ) 2 , —(CH 2 ) n —R 4 , or an optionally substituted group selected from C 1-6 aliphatic, phenyl, 3- to 7-membered saturated or partially unsaturated carbocyclyl, 3- to 7-membered saturated or partially unsaturated heterocyclyl having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 5- to 6-membered monocyclic heteroaryl having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; or

two occurrences of R 2 , taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered saturated or partially unsaturated heterocyclyl having 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;

each R 3 is independently —(CH 2 ) n —R 4 ; or

two occurrences of R 3 , taken together with the atom(s) to which they are attached, form optionally substituted 5- to 6-membered saturated or partially unsaturated heterocyclyl having 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;

each R 4 is independently hydrogen, —OR 5 , —N(R 5 ) 2 , —OC(O)R 5 , —OC(O)OR 5 , —CN, —C(O)N(R 5 ) 2 , —NR 5 C(O)R 5 , —OC(O)N(R 5 ) 2 , —N(R 5 )C(O)OR 5 , —NR 5 S(O) 2 R 5 , —NR 5 C(O)N(R 5 ) 2 , —NR 5 C(S)N(R 5 ) 2 , —NR 5 C(NR 5 )N(R 5 ) 2 , or

each R 5 is independently hydrogen or optionally substituted C 1-6 aliphatic; or

two occurrences of R 5 , taken together with the atom(s) to which they are attached, form optionally substituted 4- to 7-membered saturated or partially unsaturated heterocyclyl having 0-1 additional heteroatom selected from nitrogen, oxygen, and sulfur;

each R b is independently hydrogen or an optionally substituted C 1-6 aliphatic group; and

each n is independently 0, 1, 2, 3, or 4.

2 . The compound of claim 1 , wherein the compound is of Formula I:

or its N-oxide, or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 or 2 , wherein the compound is of Formula I-A:

or its N-oxide, or a pharmaceutically acceptable salt thereof.

4 . The compound of any one of claims 1-3 , wherein the compound is of Formula II:

or its N-oxide, or a pharmaceutically acceptable salt thereof, wherein

each of L 3a′ and L 3a″ is independently absent or an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-10 hydrocarbon chain, wherein 1-5 methylene units are optionally and independently replaced with —O— or —NR b —;

each of R a′ and R a″ is independently hydrogen or an optionally substituted group selected from

C 6-20 aliphatic, 3- to 12-membered saturated or partially unsaturated carbocyclyl, 7- to 12-membered saturated or partially unsaturated bridged bicyclyl having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 1-adamantyl, 2-adamantyl, sterolyl, and phenyl.

5 . The compound of any one of claims 1-4 , wherein the compound is of Formula II-A:

or its N-oxide, or a pharmaceutically acceptable salt thereof.

6 . The compound of any one of claims 1-5 , wherein the compound is of Formula III:

or its N-oxide, or a pharmaceutically acceptable salt thereof.

7 . The compound of any one of claims 1-6 , wherein the compound is of Formula IIIA:

or its N-oxide, or a pharmaceutically acceptable salt thereof.

8 . The compound of any one of claims 1-7 , wherein L is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-6 hydrocarbon chain.

9 . The compound of any one of claims 1-8 , wherein L is —(CH 2 ) 2 — or —(CH 2 ) 3 —.

10 . The compound of any one of claims 1-9 , wherein L 1 is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-6 hydrocarbon chain.

11 . The compound of any one of claims 1-10 , wherein L 1 is —(CH 2 ) 2 — or —(CH 2 ) 3 —.

12 . The compound of any one of claims 1-11 , wherein L 2 is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-15 hydrocarbon chain.

13 . The compound of any one of claims 1-12 , wherein L 2′ is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-15 hydrocarbon chain.

14 . The compound of any one of claims 1-13 , wherein L 2″ is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 2-15 hydrocarbon chain.

15 . The compound of any one of claims 1-14 , wherein L 3 is absent.

16 . The compound of any one of claims 1-14 , wherein L 3 is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-5 hydrocarbon chain.

17 . The compound of any one of claims 1-16 , wherein L 3′ is absent.

18 . The compound of any one of claims 1-16 , wherein L 3′ is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-5 hydrocarbon chain.

19 . The compound of any one of claims 1-18 , wherein L 3″ is absent.

20 . The compound of any one of claims 1-18 , wherein L 3″ is an optionally substituted, bivalent saturated or unsaturated, straight or branched, C 1-5 hydrocarbon chain.

21 . The compound of any one of claims 1-20 , wherein X is —OC(O)—.

22 . The compound of any one of claims 1-20 , wherein X is —C(O)O—.

23 . The compound of any one of claims 1-22 , wherein X′ is —OC(O)—.

24 . The compound of any one of claims 1-22 , wherein X′ is —C(O)O—.

25 . The compound of any one of claims 1-24 , wherein X″ is —OC(O)—.

26 . The compound of any one of claims 1-24 , wherein X″ is —C(O)O—.

27 . The compound of any one of claims 1-26 , wherein R is

or optionally substituted C 6-20 aliphatic.

28 . The compound of any one of claims 1-27 , wherein R′ is

or optionally substituted C 6-20 aliphatic.

29 . The compound of any one of claims 1-28 , wherein R″ is

or optionally substituted C 6-20 aliphatic.

30 . The compound of any one of claims 1-29 , wherein L 3a is absent.

31 . The compound of any one of claims 1-30 , wherein L 3a′ is absent.

32 . The compound of any one of claims 1-31 , wherein L 3a″ is absent.

33 . The compound of any one of claims 1-32 , wherein each R a is independently optionally substituted C 6-12 alkenyl.

34 . The compound of any one of claims 1-33 , wherein each R a′ is independently optionally substituted C 6-12 alkenyl.

35 . The compound of any one of claims 1-34 , wherein each R a″ is independently optionally substituted C 6-12 alkenyl.

36 . The compound of any one of the preceding claims , wherein each of

is

37 . The compound of any one of the preceding claims , wherein each of -L 3 -R, -L 3′ -R′, and -L 3″ -R″ is independently

38 . The compound of any one of claims 1-37 , R 1 is —OR 2 .

39 . The compound of any one claims 1-38 , R 2 is hydrogen.

40 . A compound selected from Table 1, or a pharmaceutically acceptable salt thereof.

41 . A lipid nanoparticle (LNP) preparation comprising an ionizable lipid of any one of claims 1-40 .

42 . A lipid nanoparticle (LNP) preparation comprising:

an ionizable lipid of any one of claims 1-40 ;

a phospholipid;

a sterol; and

a conjugate-linker lipid (e.g., polyethylene glycol lipid).

43 . The LNP preparation of claim 41 or 42 , further comprising a therapeutic and/or prophylactic agent.

44 . The LNP preparation of claim 43 , wherein the therapeutic and/or prophylactic agent is or comprises one or more nucleic acids.

45 . The LNP preparation of claim 44 , wherein the one or more nucleic acids is or comprises RNA.

46 . The LNP preparation of claim 45 , wherein the one or more nucleic acids is or comprises DNA.

47 . The LNP preparation of any one of claims 43-46 , wherein the LNP preparation is formulated to deliver the therapeutic and/or prophylactic agent to target cells.

48 . The LNP preparation of claim 47 , wherein the target cells are or comprise spleen cells (e.g., splenic B cells, splenic T cells, splenic monocytes), liver cells (e.g., hepatocytes), bone marrow cells (e.g., bone marrow monocytes), immune cells, kidney cells, muscle cells, heart cells, lung cells, or cells in the central nervous system.

49 . The LNP preparation of claim 48 , wherein the target cells are or comprise hematopoietic stem cells (HSCs).

50 . A pharmaceutical composition comprising a LNP preparation of any one of claims 41-49 and a pharmaceutically acceptable excipient.

51 . A method for administering a therapeutic and/or prophylactic agent to a subject in need thereof, the method comprising administering the LNP preparation of any one of claims 41-49 or the pharmaceutical composition of claim 50 to the subject.

52 . A method for treating a disease or a disorder in a subject in need thereof, the method comprising administering the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , to the subject, wherein the therapeutic and/or prophylactic agent is effective to treat the disease.

53 . A method for delaying and/or arresting progression a disease or a disorder in a subject in need thereof, the method comprising administering the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , to the subject, wherein the therapeutic and/or prophylactic agent is effective to treat the disease.

54 . A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell derived from a subject, the method comprising contacting the cell of the subject having been administered the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 .

55 . A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , wherein the therapeutic and/or prophylactic agent is or comprises an mRNA, and wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.

56 . A method of inhibiting production of a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , wherein the therapeutic and/or prophylactic agent is or comprises an RNA, whereby the RNA is capable of inhibiting production of the polypeptide of interest.

57 . A method of specifically delivering a therapeutic and/or prophylactic agent to a mammalian organ, tissue, cell, or population of cells, the method comprising contacting a mammalian organ, tissue, cell, or population of cells with the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , whereby the therapeutic and/or prophylactic agent is delivered to the organ, tissue, cell, or population of cells.

58 . The method of claim 57 , comprising administering to a subject the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 , to the subject.

59 . A method of vaccinating by administering the LNP preparation of any one of claims 41-49 , or the pharmaceutical composition of claim 50 .

60 . A method of inducing an adaptive immune response in a subject, comprising administering to the subject an effective amount of a composition comprising at least one RNA; wherein the composition comprises a LNP preparation comprising a compound of any one of claims 1-40 , or a pharmaceutically acceptable salt thereof.